… Patients with lung cancer who respond to gefitinib have been reported to have somatic … to
gefitinib in initially gefitinib-sensitive patients. We describe a patient with gefitinib-resistant lung …

… drug for patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).
The pharmacokinetics of orally administered gefitinib varies greatly among patients. We …

… Background: Gefitinib (‘Iressa’, … patients with non-small-cell lung cancer (NSCLC) in clinical
trials. We have retrospectively analyzed the efficacy and tolerability of gefitinib in patients …

… Recently, EGFR mutations have been associated with dramatic responses to gefitinib in
patients with lung cancer. However, the rate of mutations in patients with breast cancer remains …

… Lung cancer is the most common cancer and the leading cause of cancer-related deaths in
the United States … More than 85% of lung cancer cases are classified as non-small cell lung …

… in the gefitinib arm, but treatment discontinuation rate was low (14%). A Japanese study
treated 30 lung cancer patients with activating EGFR mutations who had poor PS with gefitinib […

… was to explore the relationship between gefitinib exposure and clinical outcome in
gefitinib-treated patients with advanced non-small cell lung cancer. Thirty patients participated in this …

We previously examined the relationship between epidermal growth factor receptor (EGFR)
status and clinical outcomes of nonsmall‐cell lung cancer (NSCLC) patients treated with …

… Paul Bunn: The preclinical trials show A431 as an aberrant cell line, and they showed that
15% of lung cancer cells in vitro have a great response to gefitinib, and that’s the same as the …

… gefitinib (IRESSA*), greater efficacy was observed in Japanese compared with non‑Japanese
patients… Evaluation in Lung cancer [ISEL]) showed that treatment with gefitinib was not …